Actuate Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $14.5M
Latest Deal Amount
  • Investors
  • 5

Actuate Therapeutics General Information

Description

Operator of a clinical-stage biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis. The company is developing novel therapeutics that target Glycogen Synthase Kinase-3β (GSK-3β) that have implications in conditions, including cancer, Alzheimer's disease, bipolar disorder, diabetes mellitus type II, and inflammatory conditions leading to fibrosis, empowering healthcare providers for the treatment of cancer and fibrotic diseases.

Contact Information

Formerly Known As
Apotheca Therapeutics, Inc.
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 1751 River Run
  • Suite 400
  • Fort Worth, TX 76107
  • United States
+1 (847) 000-0000

Actuate Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Actuate Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 10-Dec-2020 $14.5M 000.00 000.00 Completed Generating Revenue
3. Early Stage VC (Series B3) 12-Nov-2019 00.00 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 30-Apr-2019 $21.7M $24.7M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 15-Jun-2017 $3M $3M 000 Completed Generating Revenue
To view Actuate Therapeutics’s complete valuation and funding history, request access »

Actuate Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-4 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B-3 0,000,000 00.000000 00 00 00 00 00 00.000
Series B-2 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B-1 4,133,477 $0.000001 8% $3.66 $3.66 1x $3.66 26.79%
Series A 1,983,663 $0.000001 8% $2 $2 1x $2 12.86%
To view Actuate Therapeutics’s complete cap table history, request access »

Actuate Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a clinical-stage biopharmaceutical company focused on the development of compounds for use in the treatment
Drug Discovery
Fort Worth, TX
6 As of 2021
000.00
00.00 0000-00-00
00000000000 000.00

00000 00

etur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
0000 000000000
Geneva, Switzerland
00 As of 0000
00000
00000000000 00000

00000000

m, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irur
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Actuate Therapeutics Competitors (56)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Light Chain Bioscience Venture Capital-Backed Geneva, Switzerland 00 00000 00000000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000 Venture Capital-Backed Utrecht, Netherlands 00 00.000 0000000000 0 00.000
000000000 00000000 Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
00000 000000000000 Formerly VC-backed Waltham, MA 00 00000 00000000 00000
You’re viewing 5 of 56 competitors. Get the full list »

Actuate Therapeutics Patents

Actuate Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210228546-A1 Methods of treating malignant lymphoproliferative disorders Pending 05-Jun-2018 00000000000
AU-2019280693-A1 Methods of treating malignant lymphoproliferative disorders Pending 05-Jun-2018 00000000000
CA-3102555-A1 Methods of treating malignant lymphoproliferative disorders Pending 05-Jun-2018 00000000000
EP-3801768-A1 Methods of treating malignant lymphoproliferative disorders Pending 05-Jun-2018 00000000000
US-20210212988-A1 Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors Pending 17-May-2018 A61K31/407

Actuate Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Daniel Schmitt Co-Founder, President, Chief Executive Officer & Board Member
Francis Giles MD Chief Medical Officer
Andrew Mazar Ph.D Scientific Co-Founder
Aaron Fletcher Ph.D Chairman
You’re viewing 4 of 5 executive team members. Get the full list »

Actuate Therapeutics Board Members (5)

Name Representing Role Since
Aaron Fletcher Ph.D Self Chairman 000 0000
Alex Andrianopoulos Self Board Member 000 0000
Leslie Kreis Jr. Bios Partners Board Member 000 0000
Neil Bajpayee Ph.D Kairos Ventures Board Member 000 0000
Pascal Krotee Ph.D Kairos Ventures Board Member 000 0000
To view Actuate Therapeutics’s complete board members history, request access »

Actuate Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Actuate Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
DEFTA Partners Venture Capital Minority 000 0000 000000 0
Kairos Ventures Venture Capital Minority 000 0000 000000 0
Bios Partners Venture Capital Minority 000 0000 000000 0
Illinois Ventures Venture Capital Minority 000 0000 000000 0
Tech Coast Angels Angel Group Minority 000 0000 000000 0
To view Actuate Therapeutics’s complete investors history, request access »